Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus Proton Therapy for Oropharyngeal Squamous Cell Carcinoma.

[1]  A. Garden,et al.  Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  Steven J Frank,et al.  Intensity-Modulated Proton Therapy ( IMPT ) versus Intensity-Modulated Photon Radiotherapy ( IMRT ) for Oropharyngeal Cancer : First Comparative Results of Patient-Reported Outcomes , 2016 .

[3]  A. Garden,et al.  A multi‐institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity‐modulated radiotherapy , 2015, Cancer.

[4]  P. Catalano,et al.  Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era , 2015, Cancer.

[5]  Erik W. Korevaar,et al.  Robust Intensity Modulated Proton Therapy (IMPT) Increases Estimated Clinical Benefit in Head and Neck Cancer Patients , 2016, PloS one.

[6]  R. Mohan,et al.  Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. , 2016, International journal of radiation oncology, biology, physics.

[7]  Steffen Löck,et al.  Identification of Patient Benefit From Proton Therapy for Advanced Head and Neck Cancer Patients Based on Individual and Subgroup Normal Tissue Complication Probability Analysis. , 2015, International journal of radiation oncology, biology, physics.

[8]  R. Tishler,et al.  Cost-Effectiveness Analysis of Chemoradiation Therapy Versus Transoral Robotic Surgery for Human Papillomavirus-Associated, Clinical N2 Oropharyngeal Cancer. , 2016, International journal of radiation oncology, biology, physics.

[9]  Steven J Frank,et al.  Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  Hanne M Kooy,et al.  Dose uncertainties in IMPT for oropharyngeal cancer in the presence of anatomical, range, and setup errors. , 2013, International journal of radiation oncology, biology, physics.

[11]  A. Lühr,et al.  NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy , 2015, Acta oncologica.

[12]  P. Lambin,et al.  The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy. , 2011, Oral oncology.

[13]  S. Hahn,et al.  Proton therapy for head and neck cancer , 2015, Current opinion in oncology.

[14]  Arjen van der Schaaf,et al.  The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: A planning comparative study , 2013, Acta oncologica.

[15]  K. Ang,et al.  Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Chung,et al.  E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Esther Kim,et al.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Genden,et al.  Preferences and utilities for health states after treatment for oropharyngeal cancer: Transoral robotic surgery versus definitive (chemo)radiotherapy , 2014, Head & neck.

[19]  Amy Y. Chen,et al.  Temporal trends in oropharyngeal cancer treatment and survival: 1998–2009 , 2014, The Laryngoscope.

[20]  Emma Hall,et al.  Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial , 2011, The Lancet. Oncology.

[21]  Jeff Z. Y. Chen,et al.  Early-stage squamous cell carcinoma of the oropharynx: Radiotherapy vs. Trans-Oral Robotic Surgery (ORATOR) – study protocol for a randomized phase II trial , 2013, BMC Cancer.

[22]  A. Garden,et al.  Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. , 2016, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[23]  F. Feng,et al.  Predictors of Dysgeusia in Patients With Oropharyngeal Cancer Treated With Chemotherapy and Intensity Modulated Radiation Therapy. , 2016, International journal of radiation oncology, biology, physics.

[24]  A. Garden,et al.  Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Lihong Qi,et al.  Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[26]  B. O'Sullivan,et al.  Cost-Effectiveness Analysis of Radiation Therapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma. , 2017, International journal of radiation oncology, biology, physics.

[27]  T. Le,et al.  Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients , 2012, Journal of medical economics.

[28]  T. Trikalinos,et al.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.